Category Archives: Survival prostate cancer

Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy

Posted on April 24, 2015 by

Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author:  Anthony V. D’Amico Source: Clinical Genitourinary Cancer.  March 5, 2015

Posted in Biopsy, Prognosis, Prostate Cancer, PSA, Survival prostate cancer, Treatments for Prostate Cancer | Leave a comment

PSA Response to Neoadjuvant Androgen Deprivation Therapy iIs a Strong Predictor of Survival

Posted on June 2, 2013 by

PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

Posted in Hormonal Blockade, Prognosis, Prostate Cancer, PSA, Radiation Therapy, Survival prostate cancer, Treatments for Prostate Cancer | Tagged | Leave a comment

What is Prolactin and why is it important?

Posted on March 20, 2012 by

Question of the week:   What is Prolactin and why is it important?    The article of the week: Prolactin in men’s health and disease.  Alexander Bolyakov; Current Opinion in Urology 2011, 21:527–534   Dr. Barken answers the questions and presents a … Continue reading →

Posted in Castration Resistant Prostate Cancer, Checklist, Coaching, Hormonal Blockade, Journal Club, Markers, Metastatic Disease, Sexual Dysfunction, Survival prostate cancer, Testosterone, Treatments for Prostate Cancer | Tagged , | Leave a comment

Radium-223 ( Alpharadin): A novel Radiopharmaceutical that Prolongs Survival in Bone Metastatic Disease

Posted on March 13, 2012 by

  The following question is for the Ask Dr Barken Call In Show on Tuesday, March 13th at 6pm Pacific Time.  Dial 1-877-727-3301 to hear the program. Where can I get Alpharadin? What criteria will I need to meet to get … Continue reading →

Posted in Ask Dr. Barken, Bone Metastases, Castration Resistant Prostate Cancer, Metastatic Disease, Metastatic Prostate Cancer Disease, Prostate Cancer, Radiation treatment, Survival prostate cancer, Treatments for Prostate Cancer | Tagged , | Leave a comment

Ask Dr. Barken – C-Reactive Protein

Posted on January 23, 2012 by

The following question is for the Ask Dr Barken Call In Show on Tuesday, Jan. 24th at 6pm Pacific Time.  Dial 1-877-727-3301 to hear the program. Question of the week:   What is C-Reactive Protein?  When should you use it as a marker? … Continue reading →

Posted in Ask Dr. Barken, Diagnosis, Markers, Prognosis, Prostate Cancer, Survival prostate cancer, Treatments for Prostate Cancer | Tagged | Leave a comment

Advice to a Newly Diagnosed Prostate Cancer Patient

Posted on November 8, 2011 by

It is initially devastating for a patient to hear his doctor tell him that he has prostate cancer. As Dr. Barken likes to tell patients: “”Prostate cancer is not a death sentence – it’s a declaration of war!”. In this … Continue reading →

Posted in Active Surveillance, Diagnosis, Prognosis, Survival prostate cancer, Treatments for Prostate Cancer | Leave a comment

Imaging and the Treatment of Nodal Disease in Prostate Cancer

Posted on July 26, 2011 by

Dr. Urs Struder lectures at the AUA annual meeting 2011.

Posted in Radical Prostatectomy, Survival prostate cancer, Treatments for Prostate Cancer | Tagged | Leave a comment

Risk of Death From Prostate Cancer After Radical Prostatectomy or Brachytherapy in Men With Low or Intermediate Risk Disease (Video)

Posted on July 14, 2011 by

Dr. Barken discusses a journal article from the Journal of Urology.

Posted in Radiation treatment, Radical Prostatectomy, Survival prostate cancer | Tagged , | 2 Comments

Metastatic disease after Radical Prostatectomy or Radiation

Posted on June 16, 2011 by
Posted in Radical Prostatectomy, Survival prostate cancer | Tagged , , | Leave a comment